Anupam Rasayan India Ltd. has signed an agreement to acquire up to 43.3% stake in pharmaceutical formulations company Bliss GVS Pharma Ltd. The Surat-based company will acquire a 43.

Specialty chemicals maker Anupam Rasayan India Ltd. has signed an agreement to acquire up to 43.3% stake in pharmaceutical formulations company Bliss GVS Pharma Ltd. for an estimated Rs 1,369.51 crore and launch an open offer to acquire a further 26% in the firm, according to a statement. The Surat-based company will acquire a 43.3% stake at Rs 299 per share for Rs 1,369.51 crore, and launch a mandatory open offer for an additional 26% from public shareholders at the same price, Anupam Rasayan said in a late-night regulatory filing. "We have entered into a definitive agreement to acquire 43.3-48.2% equity stake and are making an open offer to the public shareholders of Bliss GVS Pharma," Anupam Rasayan India Managing Director Anand Desai said. The acquisition will be funded through a Rs 300 crore term loan, with the remaining amount financed via a non-controlling, non-voting equity instrument. "This will strategically strengthen our presence across the pharmaceutical value chain, spanning key starting materials to finished dosage formulations," Desai added. ALSO READ: Emirates NBD Announces Rs 11,735-Crore Open Offer For 26% Stake In RBL Bank Bliss GVS Pharma, listed on the NSE and BSE, develops and exports a range of formulations including suppositories, tablets, capsules and injectables. The company, established in 1984, holds EU-GMP certification and operates manufacturing facilities in Maharashtra and Daman with approvals from the USFDA and the World Health Organization. The company has a portfolio of over 150 branded formulations and is among India's largest manufacturers of suppositories and pessaries, with a strong presence across Africa, Asia, and Latin America. Anupam Rasayan said the combined entity would create an integrated pharmaceutical manufacturing platform with deeper backward integration and expanded reach in regulated markets, including Europe and the United States, aided by its earlier acquisition of Jayhawk. The specialty chemicals maker reported a 40% jump in consolidated net profit to Rs 222.19 crore for fiscal year 2025-26, up from Rs 159.9 crore a year earlier. ALSO READ: Adani Ports to Acquire Jaypee Fertilizers For Rs 1,500 Crore

China's wholesale prices rose at the fastest pace in nearly four years in May.

Trump Media & Technology Group (DJT) has drawn fresh attention after recent share price swings.

On June 9, 2026, the tech-heavy Nasdaq Composite plunged 2.17%, losing more than 560 points as AI and semiconductor stocks extended their sell-off.